TORONTO – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN), (OTCQB:KHRNF), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce that, further to its February 11, 2020 press release, the Company has received final approval from the TSX Venture Exchange (the “TSXV”) for a normal course issuer bid to repurchase, for cancellation, up to 5,830,615 common shares of the Company (“Shares”), representing approximately 5% of the Company’s presently issued and outstanding Shares (the “NCIB”).
Purchases under the NCIB will commence on or about March 4, 2020 and will expire on the earlier of: (i) one year from such commencement; or (ii) the date on which the Company has purchased the maximum number of Shares to be acquired under the NCIB. The NCIB will be conducted on behalf of the Company by Scotia Capital Inc. The purchase and payment for the Shares will be made in accordance with TSXV requirements at the market price of the applicable securities at the time of acquisition, plus applicable brokerage fees. The actual number of Shares that may be purchased and the timing of any such purchases will be determined at management’s discretion and will be made in accordance with the requirements of the TSXV.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The company delivers best in class regulatory compliance, has the first approved set of CBD cosmetic products on shelf in Colombia, and is currently facilitating testing to meet and surpass all license requirements for commercial cannabis derived products.
With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.